1.

Effects on muscle performance of NSAID treatment with piroxicam versus placebo in geriatric patients with acute infection-induced inflammation. A double blind randomized controlled...

2.

Effects on muscle performance of NSAID treatment with piroxicam versus placebo in geriatric patients with acute infection-induced inflammation. A double blind randomized controlled...

3.

Effects on muscle performance of NSAID treatment with piroxicam versus placebo in geriatric patients with acute infection-induced inflammation. A double blind randomized controlled...

4.

Effects on muscle performance of NSAID treatment with piroxicam versus placebo in geriatric patients with acute infection-induced inflammation. A double blind randomized controlled...

1.

Fig 6 -

2.

Fig 6 -

3.

Fig 6 -

4.

Fig 6 -

5.

Fig 6 -

6.

Fig 6 -

7.

Fig 6 -

8.

Fig 6 -

9.

Fig 6 -

1.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

2.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

3.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

4.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

5.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

6.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

7.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

8.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

9.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

1.

S2 Fig -

2.

S2 Fig -

3.

S2 Fig -

4.

S2 Fig -

5.

S2 Fig -

6.

S2 Fig -

7.

S2 Fig -

8.

S2 Fig -

9.

S2 Fig -

1.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

2.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

3.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

4.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

5.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

6.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

7.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

8.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

9.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

1.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

2.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

3.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

4.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

5.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

6.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

7.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

8.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

9.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

1.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

2.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

3.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

4.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

5.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

6.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

7.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

8.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

9.

Overview of sampling dates, sites sampled per measurement, number of samples collected per measurement and presence of colistin-resistant Enterobacterales.

1.

Colistin use per farm expressed as TiDDDVet.

2.

Colistin use per farm expressed as TiDDDVet.

3.

Colistin use per farm expressed as TiDDDVet.

4.

Colistin use per farm expressed as TiDDDVet.

5.

Colistin use per farm expressed as TiDDDVet.

6.

Colistin use per farm expressed as TiDDDVet.

7.

Colistin use per farm expressed as TiDDDVet.

8.

Colistin use per farm expressed as TiDDDVet.

9.

Colistin use per farm expressed as TiDDDVet.

1.

Sequenced isolates and their phenotypic and genotypic characteristics.

2.

Sequenced isolates and their phenotypic and genotypic characteristics.

3.

Sequenced isolates and their phenotypic and genotypic characteristics.

4.

Sequenced isolates and their phenotypic and genotypic characteristics.

5.

Sequenced isolates and their phenotypic and genotypic characteristics.

6.

Sequenced isolates and their phenotypic and genotypic characteristics.

7.

Sequenced isolates and their phenotypic and genotypic characteristics.

8.

Sequenced isolates and their phenotypic and genotypic characteristics.

9.

Sequenced isolates and their phenotypic and genotypic characteristics.

1.

Genomes used as reference for the detection of mutations linked to colistin resistance.

2.

Genomes used as reference for the detection of mutations linked to colistin resistance.

3.

Genomes used as reference for the detection of mutations linked to colistin resistance.

4.

Genomes used as reference for the detection of mutations linked to colistin resistance.

5.

Genomes used as reference for the detection of mutations linked to colistin resistance.

6.

Genomes used as reference for the detection of mutations linked to colistin resistance.

7.

Genomes used as reference for the detection of mutations linked to colistin resistance.

8.

Genomes used as reference for the detection of mutations linked to colistin resistance.

9.

Genomes used as reference for the detection of mutations linked to colistin resistance.